SynthesisEuropean journal of clinical investigation2026
The high-density lipoprotein lipidome in metabolic syndrome: A systematic review.
Synthesis in European journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMetabolic syndrome (MetS) is a cluster of cardiovascular risk factors, including low high-density lipoprotein cholesterol (HDL-C) levels. Although HDL-C is an established cardiovascular biomarker, in MetS this marker captures only a fraction of the profound alterations occurring within HDL particles. The cardiometabolic role of HDLs in MetS remains insufficiently understood because the functional properties and molecular components of HDLs, rather than HDL-C alone, are likely key determinants of cardiovascular risk. Since the early 2000s, research has revealed that HDL particles comprise over 280 proteins and more than 300 lipid species, underscoring their biological complexity. Moreover, HDL composition and function are extensively remodelled in MetS, highlighting the importance of characterising the differences in HDL composition between health and disease. In this systematic review, we aimed to examine differences in the HDL lipidome between MetS patients and healthy controls.
methodsA comprehensive literature search was conducted in MEDLINE, Cochrane Library, and Web of Science. The PRISMA guidelines for systematic reviews were followed, and four records met the eligibility criteria.
resultsOverall, the HDL lipidome was markedly different in MetS compared with healthy individuals. MetS was consistently associated with higher levels of triacylglycerides (TAGs) and phosphatidylinositol, alongside lower levels of several key lipid families, indicating a broad remodelling of HDL composition.
conclusionsThese findings indicate that the HDL lipidome is substantially altered in MetS, with potential consequences for HDL functionality. Although the mechanistic implications remain to be fully elucidated, TAG enrichment may contribute to lower HDL levels and changes in HDL surface lipids may impair essential functions such as cholesterol efflux. Further studies are needed to validate these patterns and determine their impact on HDL function and cardiometabolic risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.